Predicting in vivo cardiovascular properties of β-blockers from cellular assays: A quantitative comparison of cellular and cardiovascular pharmacological responses

FASEB Journal

Volumn 25, Issue 12, 2011, Pages 4486-4497

  Baker, Jillian G ^a   Kemp, Philip ^a   March, Julie ^a   Fretwell, Laurice ^a   Hill, Stephen J ^a   Gardiner, Sheila M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

adrenoceptor; Heart rate; Intrinsic sympathomimetic activity; Partial agonism; Vascular conductance

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 [2 [(2 HYDROXY 3 PHENOXYPROPYL)AMINO]ETHOXY] N (2 METHOXYETHYL)PHENOXYACETAMIDE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ACEBUTOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; ISOPRENALINE; LABETOLOL; NEBIVOLOL; PRONETALOL; UNCLASSIFIED DRUG; XAMOTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CONDUCTANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; HEART RATE; HINDQUARTERS VASCULAR CONDUCTANCE; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOVASCULAR AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; HEART RATE; HUMANS; IMIDAZOLES; ISOPROTERENOL; MALE; PHENOXYACETATES; PHENOXYPROPANOLAMINES; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE; XAMOTEROL;

EID: 82655181354     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.11-192435     Document Type: Article

References (57)

1. Black, J. W., Duncan, W. A. M., and Shanks, R. G. (1965) Comparison of some properties of pronethalol and propranolol. Br. J. Pharmacol. 25, 577-591
2. Hollenberg, N. K. (2005)The role of β-blockers as a cornerstone of cardiovascular therapy. Am. J. Hypertens. 18, 165S-168S
3. Baker, J. G., Hill, S. J., and Summers, R. J. (2011)Evolution of β-blockers - from anti-anginal drugs to ligand-directed signalling Trends Pharmacol Sci. 32, 227-234
4. Auerbach, A. D., and Goldman, L. (2002) Beta-blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA 287, 1435-1444 (Pubitemid 34250507)
5. Ellison, K. E., and Gandhi, G. (2005) Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs 65, 787-797 (Pubitemid 40593627)
6. Bangalore, S., Messerli, F. H., Kostis, J. B., and Pepine, C. J. (2007) Cardiovascular protection using beta-blockers: a critical review of the evidence. J. Am. Coll. Cardiol. 50, 563-572 (Pubitemid 47202065)
7. Echahidi, N., Pibarot, P., O'Hara, G., and Mathieu, P. (2008) Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J. Am. Coll. Cardiol. 51, 793-801 (Pubitemid 351255619)
8. Aronow, W. S. (2010) Current role of beta-blockers in the treatment of hypertension. Expert Opin. Pharmacother. 11, 2599-2607
9. Cruickshank, J. M. Beta-blockers and hypertension. (2010) J. Am. Coll. Cardiol. 53, 2105-2106
10. Cruickshank, J. M. (2007) Are we misunderstanding beta-blockers. Int. J. Cardiol. 20, 10-27
11. Peet, M., and Yates, R. A. (1981) Beta-blockers in the treatment of neurological and psychiatric disorders. J. Clin. Hosp. Pharm. 6, 155-171 (Pubitemid 12230810)
12. Feely, J., and Peden, N. (1984) Use of beta-adrenoceptor blocking drugs in hyperthyroidism. Drugs 27, 425-446 (Pubitemid 14130528)
13. Uitti, R. J. (1998) Medical treatment of essential tremor and Parkinson's disease. Geriatrics 53, 46-48 and 53-57
14. Gray, R. N., Goslin, R. E., McCrory, D. C., Eberlein, K., Tulsky, J., and Hasselblad, V. (1999) Drug Treatments for the Prevention of Migraine Headache. AHRQ Technical Reviews and Summaries, U.S. Agency for Health Care Policy and Research, Rockville, MD, USA
15. Limmroth, V., and Michel, M. C. (2001) The prevention of migraine: a critical review with special emphasis of β-adrenergic blockers. Br. J. Clin. Pharmacol. 52, 237-243 (Pubitemid 33796220)
16. Stamper, R. L., Wiggington, S. A., and Higgingbotham, E. J. (2002) Primary drug treatment for glaucoma: beta-blocker versus other medications. Surv. Ophthalmol. 47, 63-67 (Pubitemid 34099000)
17. Willette, R. N., Aiyar, N., Yue, T. L., Mitchell, M. P., Disa, J., Storer, B. L., Naselsky, D. P., Stadel, J. M., Ohlstein, E. H., and Ruffolo, R.R. Jr. (1999) In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J. Pharmacol. Exp. Ther. 289, 48-53 (Pubitemid 29156011)
18. Wollert, K. C., and Drexler, H. (2002) Carvedilol prospective randomized cumulative survival (COPERNICUS) trial carvedilol as the sun and center of the β-blocker world? Circulation 106, 2164-2166 (Pubitemid 35222205)
19. Metra, M., Cas, L. D., di Lenarda, A., and Poole-Wilson, P. (2004) Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail. Rev. 9, 123-130 (Pubitemid 39485473)
20. Karter, Y. (2007) Nebivolol: more than a highly selective beta blocker. Recent Pat. Cardiovasc. Drug Discov. 2, 152-155
21. Kountz, D. S. (2009) Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension? Postgrad. Med. 121, 14-24
22. Basile, J. N. (2010) One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk. Am. J. Med. 123, S9-S15
23. Lipsic, E., and Van Veldhuisen, D. J. (2010) Nebivolol in chronic heart failure: current evidence and future perspectives. Expert Opin. Pharmacother. 11, 983-992
24. Waagstein, F., Hjalmarson, A., Varnauskas, E., and Wallentin, I. (1975) Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart J. 37, 1022-1036
25. Swedberg, K., Hjalmarson, A., Waagstein, F., and Wallentin, I. (1979) Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1, 1374-1376 (Pubitemid 9204152)
26. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. (1999) Lancet 353, 9-13
27. Packer, M., Fowler, M. B., Roecker, E. B., Coats, A. J. S., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Staiger, C., Holcslaw, T. L., Amann-Zalan, I., and DeMets, D. L., for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106, 2194-2199 (Pubitemid 35222212)
28. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). (1999) Lancet 353, 2001-2007
29. Flather, M. D., Shibata, M. C., Coats, A. J., Van Veldhuisen, D. J., Parkhomenko, A., Borbola, J., Cohen-Solal, A., Dumitrascu, D., Ferrari, R., Lechat, P., Soler-Soler, J., Tavazzi, L., Spinarova, L., Toman, J., Böhm, M., Anker, S. D., Thompson, S. G., and Poole-Wilson, P. A. (2005) SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26, 215-225 (Pubitemid 40222359)
30. Beta-blocker Evaluation of Survival Trial Investigators (BEST). (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344, 1659-1667
31. Nicholas, G., Oakley, C., Pouleur, H., Rousseau, M. F., Ryden, L. E., and Wellens, H. (1990) Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 336, 1-6
32. Poole-Wilson, P. A., Swedberg, K., Cleland, J. G., Di, Lenarda. A., Hanrath, P., Komajda, M., Lubsen, J., Lutiger, B., Metra, M., Remme, W. J., Torp-Pedersen, C., Scherhag, A., and Skene, A. (2003) Carvedilol or metoprolol European trial investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet 362, 7-13 (Pubitemid 36835815)
33. Baker, J. G. (2005) The selectivity of --adrenoceptor antagonists at the β1, β2 and β3 adrenoceptors. Br. J. Pharmacol. 144, 317-322
34. Baker, J. G. (2010) The selectivity of β-adrenoceptor agonists at the human β1, β2 and β3 adrenoceptors. Br. J. Pharmacol. 160, 1048-1061
35. Hoffmann, C., Leitz, M. R., Oberdorf-Maass, S., Lohse, M. J., and Klotz, K. N. (2004) Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptor in CHO cells. Naunyn-Schmiedebergs Arch. Pharmacol. 369, 151-159 (Pubitemid 38270770)
36. Smith, C., and Teitler, M. (1999) Beta-blocker selectivity at cloned human beta1- and beta2-adrenoceptors. Cardiovasc. Drugs Ther. 13, 123-126 (Pubitemid 29224837)
37. Maack, C., Cremers, B., Flesch, M., Höper, A., Südkamp, M., and Böhm, M. (2000) Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br. J. Pharmacol. 130, 1131-1139 (Pubitemid 30453549)
38. Andreka, P., Aiyar, N., Olson, L. C., Wei, J. Q., Turner, M. S., Webster, K. A., Ohlstein, E. H., and Bishopric, N. H. (2002) Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 105, 2429-2434 (Pubitemid 34556397)
39. Jasper, J. R., Michel, M. C., and Insel, P. A. (1988) Molecular mechanism of beta-adrenergic receptor blockers with intrinsic sympathomimetic activity. FASEB J. 2, 2891-2894
40. Jasper, J. R., Michel, M. C., and Insel, P. A. (1990) Amplification of cyclic AMP generation reveals agonistic effects of certain beta-adrenergic antagonists. Mol. Pharmacol. 37, 44-49 (Pubitemid 20038448)
41. Joseph, S. S., Lynham, J. A., Molenaar, P., Grace, A. A., Colledge, W. H., and Kaumann, A. J. (2003) Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch. Pharmacol. 368, 496-503 (Pubitemid 38041313)
42. Baker, J. G., Hall, I. P., and Hill, S. J. (2003) Agonist actions of "β-blockers" provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol. Pharmacol. 63, 1312-1321 (Pubitemid 36627226)
43. Baker, J. G., Hall, I. P., and Hill, S. J. (2003) Agonist and inverse agonist actions of "β-blockers" at the human β2-adrenoceptor provide evidence for agonist-directed signalling. Mol. Pharmacol. 64, 1357-1369 (Pubitemid 37532226)
44. Baker, J. G. (2005) Sites of action of β-ligands at the human β1-adrenoceptor. J. Pharmacol. Exp. Ther. 313, 1163-1171
45. Bundkirchen, A., Brixius, K., Bölck, B., and Schwinger, R. H. (2002) Bucindolol exerts agonistic activity on the propranololin-sensitive state of beta1-adrenoceptors in human myocardium. J. Pharmacol. Exp. Ther. 300, 794-801 (Pubitemid 34164981)
46. Donaldson, J., Brown, A. M., and Hill, S. J. (1988) Influence of rolipram on the cyclic-3′, 5′-adenosine monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex. Biochem. Pharmacol. 37, 715-723 (Pubitemid 18054551)
47. Pauwels, P. J., Gommeren, W., Van Lommen, G., Janssen, P. A., and Leysen, J. E. (1988) The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol. Pharmacol. 34, 843-851 (Pubitemid 19014407)
48. Pauwels, P. J., Van Gompel, P., and Leysen, J. E. (1991) Human beta 1- and beta 2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of nebivolol and known beta-adrenergic blockers. Biochem. Pharmacol. 42, 1683-1689
49. Azzi, M., Charest, P. G., Angers, S., Rousseau, G., Kohout, T., Bouvier, M., and Pineyro, G. (2003) --arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 100, 11406-11411 (Pubitemid 37205948)
50. Galandrin, S., Oligny-Longpre, G., Bonin, H., Ogawa, K., Gales, C., and Bouvier, M. (2008) Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol. Pharmacol. 74, 162-172 (Pubitemid 351872167)
51. Galandrin, S., and Bouvier, M. (2006) Distinct signaling profiles of â1 and â2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol.Pharmacol. 70, 1575-1584
52. Arch, J. R. (2004) Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine? Br. J. Pharmacol. 143, 517-518
53. Granneman, J. G. (2001) The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am. J. Physiol. Endocrinol. Metab. 280, E199-E202
54. Kaumann, A. J., and Molenaar, P. (2008) The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol. Ther. 118, 303-336
55. Molenaar, P. (2003) The 'state' of beta-adrenoceptors. Br. J. Pharmacol. 140, 1-2
56. Maack, C., Böhm, M., Vlaskin, L., Dabew, E., Lorenz, K., Schäfers, H. J., Lohse, M. J., and Engelhardt, S. (2003) Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor. Circulation 108, 348-353 (Pubitemid 36899028)
57. Walter, M., Lemoine, H., and Kaumann, A. J. (1984) Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of beta-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn Schmiedebergs Arch. Pharmacol. 327, 159-175 (Pubitemid 14066545)